MeiraGTx(US:MGTX) GlobeNewswire News Roomยท2025-04-29 11:11Core Insights - The cone rod dystrophy market is projected to grow from US$131.29 million in 2024 to US$177.59 million by 2030, driven by increased awareness and demand for effective treatments [2][3] - The market is expected to experience a compound annual growth rate (CAGR) of 5.33% from 2025 to 2030 [3] Market Segmentation Analysis - X-Linked Cone Rod Dystrophy is the leading type in the market, with ongoing research into gene therapies and neuroprotective agents [4] - Gene therapy holds the highest market share in treatment options, particularly through adeno-associated virus vectors [4] - Hospitals dominate the end user segment, benefiting from advanced treatment options and expanding infrastructure, especially in emerging markets [5] Regional Insights - North America leads the market due to high prevalence of eye disorders and technological advancements [6] - Asia Pacific is the fastest-growing region, with significant contributions from China's healthcare investments and Japan's market share [6] Market Dynamics - Growth drivers include rising incidence of cone rod dystrophy, increased R&D activities, and advancements in gene therapy [7] - Challenges include a limited patient pool and inconsistency in insurance coverage [7] - Trends such as early detection and personalized medicine are improving the market environment for new therapies [7] Competitive Landscape - Key players include SparingVision, Beacon Therapeutics, and Nanoscope Therapeutics, with mergers and acquisitions shaping the market [8] - Notable product SPVN06 from SparingVision is undergoing trials for various genetic mutations associated with Retinitis Pigmentosa [8]